1] Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milano, Italy [2] Molecular Genetics of Cancer, Fondazione Istituto FIRC di Oncologia Molecolare, via Adamello 16, 20139 Milano, Italy.
Unit of Medical Statistics Biometry and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milano, Italy.
Br J Cancer. 2014 Feb 18;110(4):1001-7. doi: 10.1038/bjc.2013.819. Epub 2014 Jan 14.
Plasma circulating tumour-specific microRNAs (miRNAs) are promising biomarkers of tumour presence and recurrence, especially for diseases whose best chance of successful treatment requires early diagnosis and timely surgery of an already malignant but not yet invasive tumour, such as colorectal cancer (CRC).
Expression levels of miRNAs previously found to be differently expressed in tumour vs normal colon tissues were investigated by quantitative real-time PCR in plasma from CRC patients and from healthy donors and confirmed in independent case control series. The validated miRNAs were also measured after surgery. Analyses were repeated on the subsets of haemolysis-free samples.
We identified four miRNAs differently expressed between the compared groups, two (miR-21 and miR-378) of which were validated. miR-378 expression decreased in non-relapsed patients 4-6 months after surgery and miR-378 ability to discriminate CRC patients from healthy individuals was not influenced by haemolysis levels of plasma samples.
The miRNA analysis on plasma samples represents a useful non-invasive tool to assess CRC presence as well as tumour-free status at follow-up. Plasma levels of miR-378 could be used to discriminate CRC patients from healthy individuals, irrespective of the level of haemoglobin of plasma samples.
循环肿瘤特异性 microRNAs(miRNAs)在肿瘤存在和复发方面是很有前途的生物标志物,特别是对于那些最好的治疗机会需要早期诊断和及时手术的疾病,如结直肠癌(CRC)。
通过定量实时 PCR 检测 CRC 患者和健康供体血浆中以前发现在肿瘤与正常结肠组织中表达水平不同的 miRNAs,并在独立的病例对照系列中进行了验证。在手术后也测量了验证的 miRNA。在无溶血样本的子集中进行了分析。
我们确定了两组之间有四个差异表达的 miRNA,其中两个(miR-21 和 miR-378)得到了验证。miR-378 的表达在手术后 4-6 个月无复发患者中降低,miR-378 区分 CRC 患者与健康个体的能力不受血浆样本溶血水平的影响。
对血浆样本的 miRNA 分析代表了一种有用的非侵入性工具,可以评估 CRC 的存在以及随访时的无肿瘤状态。miR-378 的血浆水平可用于区分 CRC 患者与健康个体,而与血浆样本的血红蛋白水平无关。